Regentis Biomaterials Ltd (RGNT) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access RGNT Annual Balance Sheets →
Balance sheet patterns shown here provide context for understanding Regentis Biomaterials Ltd's financial stability and long-term positioning.
Quarterly Report, GAAP in USD millions
ITEM
(Dec 31 2025)
0 0 0 (Dec 31 2024)
Assets
Cash & cash equivalent7.38
Cash & Short-term Investments7.00
Derivatives, Collateral, Regulatory, Deferred0.18
Prepaid Expense And Other Assets Current0.01
Total Current Assets7.38
Long-term investments0.01
Tax Assets, Noncurrent11.11
Other Assets, Noncurrent0.24
Total Assets7.62
Liabilities
Accounts Payable1.41
Accrued Liabilities, Current0.02
Short-term Debt DE10.20
Other Liabilities, Current0.27
Total Current Liabilities2.87
Total Long-term Debt0.00
Other liabilities, Noncurrent0.98
Total Liabilities2.87
Stockholders' Equity
Additional Paid In Capital Common Stock60.54
Retained Earnings / Accumulated Deficit-55.79
Defined Benefit Plan and Other0.00
Common Stockholder's Equity4.74
Non-controlling interests & other0.00
Total Stockholder's Equity4.74
Liabilities & Stockholder's Equity7.62
4 historic quarters locked

Sign in to unlock the full Regentis Biomaterials Ltd balance sheet history.

About Regentis Biomaterials Ltd Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 20-F filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001213900-26-019917

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.

Get the full CSIMarket dataset: Subscribe API License